ArticleInternational journal of clinical and experimental medicine2015
Cyclin D1 G870A polymorphism and glioma risk in a Chinese population.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
- CCDN1 rs603965 polymorphism may serve as a genetic biomarker of brain tumor: A meta-analysis of 5,769 subjects.Molecular genetics & genomic medicine · 2019Pooled it
- Impact of interaction between the G870A and EFEMP1 gene polymorphism on glioma risk in Chinese Han population.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA number of studies have suggested that the Cyclin D1 (CCND1) G870A polymorphism was associated with susceptibility to various cancers. In the present study, we aimed to investigate the association between CCND1 G870A polymorphism and the risk of glioma in a Chinese population. MATERIALS AND
methodsCCND1 genotyping was determined by the PCR-RFLP method. The χ (2) test was used to assess for any deviation of the genotype frequencies from Hardy-Weinberg equilibrium and to compare the genotype distributions among glioma patients and healthy control subjects. We calculated the odds ratios (ORs) and 95% confidence intervals (95% CIs) by using unconditional logistic regression.
resultsThe A allele frequency was higher in cases than that in controls (49.40% vs. 36.39%), and this difference was statistically significant (P = 0.001). Using the G allele as the reference allele, the subjects carrying the A allele had 3.926-fold increase in the risk of glioma (95% CI, 2.172-7.889), and p-value was significant (P = 0.007). Compared to individuals with the GG genotype, individuals with the AA genotype exhibited significantly increased glioma risk (OR = 3.661, 95% CI: 1.658-6.287, P = 0.01).
conclusionOur results suggest that the CCND1 G870A polymorphism may contribute to the susceptibility to glioma in Chinese population.
Indexed as
Identifiers
26309688PMC4538148W1132939337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.